Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Subscribe To Our Newsletter & Stay Updated
